A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (ROCKET-Outpost Trial)
Palo Alto (17 mi)Age: Any Age
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Recruiting
Sponsor: Amgen
No Placebo Group
Pivotal Trial (Near Approval)
Prior Safety Data
Trial Summary
What is the purpose of this trial?This trial is testing whether people can successfully give themselves rocatinlimab injections at home. Rocatinlimab is a medication that is injected under the skin. The study aims to make it easier for patients to manage their treatment without needing to visit the hospital regularly.
Eligibility Criteria
Treatment Details
3Treatment groups
Experimental Treatment
Group I: Rocatinlimab Dose 2 PFSExperimental Treatment1 Intervention
Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab for 52 weeks.
Group II: Rocatinlimab Dose 2 Autoinjector (AI)Experimental Treatment1 Intervention
Rocatinlimab will be self-administered subcutaneously using an AI. Participants will received rocatinlimab for 52 weeks.
Group III: Rocatinlimab Dose 1 Prefilled Syringe (PFS)Experimental Treatment1 Intervention
Rocatinlimab will be self-administered subcutaneously using a PFS. Participants will receive rocatinlimab for 52 weeks.
Find a clinic near you
Research locations nearbySelect from list below to view details:
Alliance Clinical TrialsWaterloo, Canada
Sms Clinical Research Limited Liability CompanyMesquite, TX
Kern Research IncBakersfield, CA
Skinsense Medical ResearchSaskatoon, Canada
More Trial Locations
Loading ...
Who is running the clinical trial?
AmgenLead Sponsor